JP2020158418A - 体力低下抑制用の医薬組成物 - Google Patents
体力低下抑制用の医薬組成物 Download PDFInfo
- Publication number
- JP2020158418A JP2020158418A JP2019057756A JP2019057756A JP2020158418A JP 2020158418 A JP2020158418 A JP 2020158418A JP 2019057756 A JP2019057756 A JP 2019057756A JP 2019057756 A JP2019057756 A JP 2019057756A JP 2020158418 A JP2020158418 A JP 2020158418A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- extract
- physical strength
- illness
- decrease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 26
- 230000007423 decrease Effects 0.000 title abstract description 26
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 239000009569 juzentaihoto Substances 0.000 claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 27
- 230000006866 deterioration Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000000843 powder Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000723438 Cercidiphyllum japonicum Species 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- -1 sedative hypnotics Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000788084 Escualosa thoracata Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明の医薬組成物は、病中及び病後以外での体力低下の抑制用途に使用されるものであって、十全大補湯及び/又はそのエキスを含有することを特徴とする。以下、本発明の医薬組成物について詳述する。
十全大補湯とは、人参、黄耆、白朮、茯苓、当帰、芍薬、地黄、川きゅう、桂皮、及び甘草からなる漢方処方である。十全大補湯を構成する各生薬の分量は、「一般用漢方処方の手引き」(厚生省薬務局監修、日薬連漢方専門委員会編集、薬業時報社発行)等によれば、人参2.5〜3質量部、黄耆2.5〜3質量部、白朮(又は蒼朮)3〜4質量部、茯苓3〜4質量部、当帰3〜4質量部、芍薬3質量部、地黄3〜4質量部、川きゅう3質量部、桂皮3質量部、及び甘草1〜2質量部である。
本発明の医薬組成物には、前述する成分以外に、必要に応じて、他の薬理成分を含んでいてもよい。このような薬理成分の種類については、特に制限されないが、例えば、消炎鎮痛剤、腸管運動改善剤、制酸剤、胃粘膜保護剤、消化剤、鎮痙剤、粘膜修復剤、収れん剤、鎮吐剤、鎮咳剤、去痰剤、消炎酵素剤、鎮静催眠剤、抗ヒスタミン剤、強心利尿剤、抗菌剤、血管収縮剤、血管拡張剤、局所麻酔剤、プロトンポンプ阻害剤、カフェイン類、メントール類、ポリフェノール等が挙げられる。これらの薬理成分は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの薬理成分の含有量については、使用する薬理成分の種類や医薬組成物の剤型等に応じて適宜設定すればよい。
本発明の医薬組成物の剤型については、特に制限されず、固体状製剤、半固体状製剤、又は液体状製剤のいずれであってもよい。
本発明の医薬組成物は、病中及び病後以外での体力低下の抑制用途に使用される。本発明において、「病中」とは病気にかかっている間を指し、「病後」とは病気が治った後の回復期間を指す。また、本発明において、「病中及び病後以外での体力低下の抑制」には、病中及び病後以外の要因で体力が低下するのを低減又は防止すること、並びに病中及び病後以外の要因で低下した体力の回復を促進することが含まれる。
6週齢のC57BL/6雄性マウス(日本エスエルシー株式会社)を1週間飼育して馴化した後に、正常群、強制歩行/コントロール群、強制歩行/十全大補湯群、及び強制歩行/ビタミン剤群の4群に分けた(1群当たり3匹)。
Claims (1)
- 十全大補湯及び/又はそのエキスを含有し、病中及び病後以外で使用される、体力低下抑制用の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019057756A JP2020158418A (ja) | 2019-03-26 | 2019-03-26 | 体力低下抑制用の医薬組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019057756A JP2020158418A (ja) | 2019-03-26 | 2019-03-26 | 体力低下抑制用の医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020158418A true JP2020158418A (ja) | 2020-10-01 |
Family
ID=72641804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019057756A Pending JP2020158418A (ja) | 2019-03-26 | 2019-03-26 | 体力低下抑制用の医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2020158418A (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10175856A (ja) * | 1996-10-14 | 1998-06-30 | Taisho Pharmaceut Co Ltd | 疲労改善剤 |
JPH10330277A (ja) * | 1997-05-30 | 1998-12-15 | Chugai Pharmaceut Co Ltd | 漢方内服液剤 |
WO2008149802A1 (ja) * | 2007-05-31 | 2008-12-11 | Suntory Holdings Limited | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 |
JP2013202061A (ja) * | 2012-03-27 | 2013-10-07 | Sumitomo Rubber Ind Ltd | 靴の歩行疲労性の評価方法 |
JP2014193903A (ja) * | 2007-03-15 | 2014-10-09 | Suntory Holdings Ltd | 抗疲労剤 |
-
2019
- 2019-03-26 JP JP2019057756A patent/JP2020158418A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10175856A (ja) * | 1996-10-14 | 1998-06-30 | Taisho Pharmaceut Co Ltd | 疲労改善剤 |
JPH10330277A (ja) * | 1997-05-30 | 1998-12-15 | Chugai Pharmaceut Co Ltd | 漢方内服液剤 |
JP2014193903A (ja) * | 2007-03-15 | 2014-10-09 | Suntory Holdings Ltd | 抗疲労剤 |
WO2008149802A1 (ja) * | 2007-05-31 | 2008-12-11 | Suntory Holdings Limited | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 |
JP2013202061A (ja) * | 2012-03-27 | 2013-10-07 | Sumitomo Rubber Ind Ltd | 靴の歩行疲労性の評価方法 |
Non-Patent Citations (2)
Title |
---|
JPN. PHARMACOL. THER., vol. 27, no. 11, JPN6022054783, 1999, pages 1737 - 1747, ISSN: 0005108032 * |
家庭薬研究, vol. 17, no. 11, JPN6022054782, 1998, pages 48 - 52, ISSN: 0005108033 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013053144A (ja) | 鎮静剤組成物 | |
KR20020092082A (ko) | 자양강장제 조성물 | |
CN106999532A (zh) | 含有复合提取物的运动执行能力增强及体力增进用组合物 | |
JPWO2014010658A1 (ja) | ヒハツ配合製剤 | |
CN110772564A (zh) | 一种具有调节抑郁情绪作用的中药提取物组合物及其制备方法和中药制剂 | |
JP2020158418A (ja) | 体力低下抑制用の医薬組成物 | |
KR20170062781A (ko) | 인지기능 개선 효능이 우수한 흑삼 추출물을 함유하는 조성물 | |
JP2018506524A (ja) | バーンアウト症候群の予防、改善、または治療用組成物 | |
US20140294998A1 (en) | Novel herbal composition | |
US20190160126A1 (en) | Compositions and methods for treating reproductive indicators symptomatic of male infertility | |
JP2021119123A (ja) | 目のピント調節改善用内服薬 | |
JP6935285B2 (ja) | 医薬組成物 | |
JP2005023008A (ja) | ビタミンb群を含有する内服液剤組成物 | |
TWI612968B (zh) | 南洋山蘇水萃物的用途 | |
JP2020158419A (ja) | 活動量改善用の医薬組成物 | |
CN101518642B (zh) | 液体内服剂 | |
JP6236489B2 (ja) | 逆流性食道炎治療薬 | |
US20130022694A1 (en) | Method for treating or relieving inflammatory bowel disease | |
JP2022022617A (ja) | 筋肉合成能促進剤 | |
JP7452777B2 (ja) | 生活の質改善又は維持用組成物 | |
CN113181205B (zh) | 包括nmn的药物组合物及其应用 | |
JP7068803B2 (ja) | 血中脂質低減用医薬組成物 | |
JPH06107553A (ja) | 鎮痛機能を有する組成物 | |
TWI440465B (zh) | 用以降血脂的中草藥萃取混合物及其醫藥組合物 | |
JP2012180331A (ja) | 筋損傷の早期回復の誘導用の経口摂取剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220209 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230508 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230718 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230915 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240130 |